Retour
SANOFI-AVENTIS (EPA:SAN) Sanofi: Information concerning the total number of voting rights and shares – March 2022
Directive transparence : information réglementée
26/04/2022 20:28
Tweeter
17/08/2022 07:30
Press Release: Sanofi provides update on amcenestrant clinical development...
08/08/2022 21:03
Sanofi: Information concerning the total number of voting rights and...
28/07/2022 14:29
Press Release: Online availability of Sanofi’s half-year financial...
20/07/2022 18:52
Sanofi: Information concerning the total number of voting rights and...
14/07/2022 07:00
Press Release: Dupixent® (dupilumab) Phase 3 trial shows positive results...
10/07/2022 15:45
Press Release: Pivotal data demonstrate once-weekly efanesoctocog alfa...
10/07/2022 15:45
Press Release: Fitusiran prophylaxis reduced bleeds by 61% in people with...
04/07/2022 12:00
Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in...
28/06/2022 07:30
Press Release: Xenpozyme® (olipudase alfa) approved by European...
28/06/2022 07:30
Press Release: Nexviadyme® (avalglucosidase alfa) approved by European...
Voir tous les communiqués de SANOFI-AVENTIS